Journal of Medical Oncology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +441518081136

Opinion Article - Journal of Medical Oncology and Therapeutics (2023) Volume 8, Issue 3

Clinical trials and their findings in oncology

Debasish Baner *

Molecular and Clinical Sciences Research Institute, St. George’s, University of London, UK

*Corresponding Author:
Debasish Baner
Molecular and Clinical Sciences Research Institute, St. George’s, University of London, UK
E-mail: debasish.baner@stgeorges.nhs.uk

Received: 19-Apr-2023, Manuscript No. JMOT-23-100259; Editor assigned: 20-Apr-2023, PreQC No. JMOT-23-100259 (PQ); Reviewed:04-May-2023, QC No. JMOT-23-100259; Revised:08-May-2023, Manuscript No. JMOT-23-100259 (R); Published:16-May-2023, DOI, DOI:10.35841/ jmot-8.3.145

Citation: Baner D . Clinical trials and their findings in oncology. J Med Oncl Ther. 2023;8(3):145

Visit for more related articles at Journal of Medical Oncology and Therapeutics

Introduction

Clinical trials are carefully designed research studies that investigate new treatments, interventions, or procedures for cancer patients. These trials aim to evaluate the safety, efficacy, and tolerability of novel therapies, compare different treatment approaches, and identify predictive biomarkers for treatment response.

Phase I trials are conducted in a small group of patients to evaluate the safety, dosage, and toxicity of a new treatment. The primary objective is to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of the investigational therapy. Phase II trials involve a larger group of patients and assess the efficacy of the treatment in specific cancer types or patient populations. These trials further evaluate safety and explore preliminary evidence of effectiveness, often using surrogate endpoints as indicators of treatment response. Phase III trials are large-scale studies that compare the new treatment to the current standard of care. These trials aim to provide definitive evidence of efficacy, assess long-term safety, and establish the new treatment's superiority or non-inferiority compared to existing options. Phase III trials often serve as the basis for regulatory approvals and changes in clinical practice [1].

Clinical trials have shown remarkable success in the field of immunotherapy, particularly immune checkpoint inhibitors targeting programmed death receptor-1 (PD-1) and programmed death-ligand 1 (PD-L1). These trials have demonstrated improved overall survival and durable responses in various cancer types, including melanoma, lung cancer, and bladder cancer. Clinical trials investigating targeted therapies have led to significant advancements in precision medicine. Findings from these trials have identified specific genetic alterations, such as EGFR mutations in lung cancer and BRAF mutations in melanoma, that guide the use of targeted agents. Targeted therapies have shown improved response rates and survival outcomes in patients harboring these biomarkers [2].

Clinical trials exploring combination therapies have provided insights into synergistic treatment approaches. For example, combining immune checkpoint inhibitors with other immunotherapies, chemotherapy, or targeted agents has demonstrated improved responses and survival outcomes in various cancer types. These findings highlight the potential of combination therapies for enhanced treatment efficacy. Clinical trials have contributed to the identification andvalidation of predictive biomarkers for treatment response. Biomarker-driven trials have shown the importance of genetic alterations, protein expression levels, and molecular signatures in selecting patients who are more likely to benefit from specific treatments. Biomarker-guided treatment strategies improve treatment outcomes and minimize unnecessary treatments for patients [3].

Clinical trial findings have a profound impact on cancer treatment and patient care. Positive trial results often lead to regulatory approvals, enabling new therapies to become standard treatment options. Negative trial results help prevent the use of ineffective or potentially harmful treatments. Clinical trial findings inform treatment guidelines, influence treatment decisions, and contribute to the development of personalized treatment approaches. They drive the evolution of oncology practice and improve patient outcomes. Patient Involvement and Patient Reported Outcomes (PROs): Patient involvement in clinical trials is crucial for understanding the patient experience, treatment preferences, and quality of life outcomes. Incorporating patient-reported outcomes (PROs) in clinical trial design allows for a comprehensive evaluation of treatment efficacy and patient satisfaction. PROs provide valuable insights into treatment tolerability, symptom management, and overall well-being, helping to shape patient centered care and optimize treatment strategies [4].

Clinical trials are essential for advancing treatments for rare cancers, which often have limited therapeutic options. Orphan drugs, which are designed to treat rare diseases or conditions, undergo clinical trials to assess their safety and effectiveness. These trials are critical for providing evidence to support the approval of orphan drugs and expanding treatment options for patients with rare cancers. The era of precision oncology relies on molecular profiling to guide treatment decisions. Clinical trials focusing on molecular profiling techniques, such as next-generation sequencing and genomic analysis, have contributed to the identification of actionable mutations and targeted therapies. These trials enable a more personalized approach to cancer treatment, improving outcomes for patients with specific genetic alterations.

In addition to traditional clinical trials, real-world evidence (RWE) studies provide valuable insights into treatment effectiveness and safety in routine clinical practice. RWE studies analyze data from electronic health records, patient registries, and other sources to evaluate treatment outcomes in a broader patient population. These studies complement clinical trials by providing evidence from real-world settings and guiding clinical decision-making. Clinical trials face challenges such as recruitment of eligible patients, ensuring diverse representation, long trial durations, and high costs. To address these challenges, innovative trial designs, such as basket trials, umbrella trials, and adaptive designs, are being explored. Collaboration among [5].

Conclusion

Clinical trials are a cornerstone of oncology research, driving progress in cancer treatment and improving patient outcomes. These carefully designed studies provide crucial evidence on the safety, efficacy, and comparative effectiveness of novel therapies, as well as the identification of predictive biomarkers and personalized treatment approaches. The findings from clinical trials shape treatment guidelines, inform treatment decisions, and contribute to the development of precision medicine in oncology.

References

  1. Holford NH, Kimko HC, Monteleone JP,et al. Annual review of pharmacology and toxicology. 2000;40(1):209-34.

    2. Indexed at, Google Scholar, Cross Ref

  2. Caldwell PH, Murphy SB, Butow PN,et al. Clinical trials in children. 2004;364(9436):803-11.

    3. Indexed at , Google Scholar, Cross Ref

  3. Kleijnen J, Knipschild P, ter Riet G. Clinical trials of homoeopathy. Br Med J. 1991;302(6772):316-23.

    4. Indexed at , Google Scholar, Cross Ref

  4. Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. J Clin Pharmacol. 2015;79(3):357-69.

    5. Indexed at , Google Scholar, Cross Ref

  5. Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. Bmj. 2001;323(7303):42-6.

    6. Indexed at , Google Scholar, Cross Ref

Get the App